The Series D financing will provide SetPoint with funding to further advance the clinical development of its bioelectronic therapy for chronic, debilitating inflammatory diseases.
This Series D round includes participation from SetPoint's existing investors, including NEA, Morgenthaler, Medtronic, Boston Scientific, Topspin, Action Potential Venture Capital, and others.
SetPoint is developing a novel proprietary bioelectronic medicine platform using a small implanted device that stimulates the vagus nerve to activate the body's natural inflammatory reflex and produces a systemic anti-inflammatory effect.
The emerging field of bioelectronic medicine aims to address unmet patient needs by delivering targeted digital doses to modulate physiological circuits to treat diseases historically treated with drugs.
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. Its approach is intended to offer patients and providers an alternative treatment for rheumatoid arthritis and other chronic inflammatory diseases with less risk and cost than drug therapy.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca